Shenzhen, November 05, 2022

IONOVA Life Science announces that data from a Phase I first-in-human study of INV-1120, a novel EP4 inhibitor, will be presented during the SITC Congress 2022.

Title: Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors

Abstract Number: 597

Presentation day: Poster Hall November 10, 2022, 9:00 am to 9:00pm

Poster Number: 597

First Author: John Sarantopoulos, Mays Cancer Center, University of Texas, San Antonio Health Science Center

According to Dr. Johannes Nippgen, Chief Medical Officer of IONOVA, "we are very excited about this unique opportunity to show the first clinical data of our compound publicly and confirm the superior profile as single agent."

About INV-1120

INV-1120 is a highly potent, highly selective, and orally available EP4 antagonist designed to modulate the tumor microenvironment. EP4 antagonists have shown to increase T cell infiltration and the level of M1 type macrophages in tumors, contributing to increased anti-cancer immune response in preclinical tumor models.


IONOVA is a clinical-stage biotech company focused on the discovery and development of innovative cancer medicines especially in the field of precision medicine and immunotherapy.